2019
DOI: 10.7748/ns.2019.e11079
|View full text |Cite
|
Sign up to set email alerts
|

Medicines management for people with dementia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 22 publications
0
1
0
Order By: Relevance
“…This low adherence may be associated with the prescription of higher number of specific drugs (e.g., acetylcholinesterase inhibitors, NMDA receptor antagonists) and polymedication with the subsequent potential greater incidence of adverse effects ( 40 ). Both scenarios together with impaired cognitive function ( 41 , 42 ) have been shown to be factors for non-adherence to treatment ( 20 , 43 , 44 ). On the other hand, another review ( 37 ) focused on the main barriers to adherence in patients with cognitive impairment, regardless the degree of impairment, and the interventions aimed to improve treatment adherence.…”
Section: Discussionmentioning
confidence: 99%
“…This low adherence may be associated with the prescription of higher number of specific drugs (e.g., acetylcholinesterase inhibitors, NMDA receptor antagonists) and polymedication with the subsequent potential greater incidence of adverse effects ( 40 ). Both scenarios together with impaired cognitive function ( 41 , 42 ) have been shown to be factors for non-adherence to treatment ( 20 , 43 , 44 ). On the other hand, another review ( 37 ) focused on the main barriers to adherence in patients with cognitive impairment, regardless the degree of impairment, and the interventions aimed to improve treatment adherence.…”
Section: Discussionmentioning
confidence: 99%